Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry.

Biochemical pharmacology - 1 Aug 2021

Scalvini Laura, Castelli Riccardo, La Monica Silvia, Tiseo Marcello, Alfieri Roberta

Abstract excerpt

Third-generation inhibitors of the epidermal growth factor receptor (EGFR), best exemplified by osimertinib, have been developed to selectively target variants of EGFR bearing activating mutations and the mutation of gatekeeper T790 in patients with EGFR-mutated forms of Non-Small Cell Lung Cancer (NSCLC). While the application of third-generation inhibitors has represented an effective first- and second-line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Mutation

Source

Identifiers

PMID: 34097913
DOI: 10.1016/j.bcp.2021.114643

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry.PMID 34097913Read ↗

Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapySemantic proximity Read ↗

Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs.Semantic proximity Read ↗

Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical reviewSemantic proximity Read ↗

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.Semantic proximity Read ↗

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancerSemantic proximity Read ↗

The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation.Semantic proximity Read ↗

Discovery of Potent and Wild-Type-Sparing Fourth-Generation EGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC.Semantic proximity Read ↗

The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies.Semantic proximity Read ↗

Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinibSemantic proximity Read ↗

Repurposing CZC54252 to target EGFR C797S mutations and conquer Osimertinib resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.